Kymera Therapeutics Inc (KYMR) — Capital Reinvestment Ratio

Latest as of December 2023: 1.44x

Kymera Therapeutics Inc (KYMR) has a Capital Reinvestment Ratio of 1.44x as of December 2023, meaning it reinvests 1% of its operating cash flow ($8.04 Million) in capital expenditures ($11.62 Million). See Kymera Therapeutics Inc balance sheet independence to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

1.44x
Capex / Operating Cash Flow

Operating Cash Flow

$8.04 Million
USD

Capital Expenditures

$11.62 Million
USD

Data as of

Dec 2023
Most recent filing

Kymera Therapeutics Inc Capital Reinvestment Ratio (2019–2020)

This chart tracks Kymera Therapeutics Inc's Capital Reinvestment Ratio across 2 annual periods. Check KYMR cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Kymera Therapeutics Inc (2019–2020)

Year-by-year Capital Reinvestment Ratio for Kymera Therapeutics Inc from 2019 to 2020. For live market cap and broader valuation context, see Kymera Therapeutics Inc market cap and net worth.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2020 0.10x $88.13 Million $9.10 Million ▲ +247.4%
2019 0.03x $17.91 Million $532.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow